Dr Rees became an Elected Member of the New York Academy of Sciences in 1981 for research studies published (1972-4) on motor nerve terminal metabolism during his Rockefeller Post-Doctoral Fellowship at the University of California (1970-73). In 1973-78 he was appointed Muscular Dystrophy Research Fellow, tenable in the Institute of Neurology, Southern General Hospital, Glasgow, where the development of Aqix was initiated using human cadaver nerve-muscle tissue biopsies. In 1978 he was appointed Senior Lecturer in Neurophysiology, Wellington Clinical School and Victoria University, New Zealand. He became Head of Research & Development and Consultant Physiologist of Res-Del Ltd, New Zealand (1980), and implemented his research into the preservation of human organs for transplant based upon his knowledge and internationally published research papers in physiology, neurophysiology, pharmacology and biotechnology. His contribution to organ preservation research over two decades and appointment as Patron of the New Zealand Muscular Dystrophy Association in 1988, led to his election as a Member of the Royal Society of New Zealand in 1997. He was appointed visiting Senior Research Fellow at King's College in the Department of Cardiac Surgical Research, and the Rayne Institute, London, where he has collaborated in the publication of a preclinical study using AQIX® RS-C, a cardioplegic variation of Aqix . His research led him to invent the means of keeping animal and human organs alive outside of the body which culminated in the patented design of the Res-Del® Isolated Tissue/Organ Perfusion System (1980) and the development of the Aqix Preservation and Perfusion medium, which he went on to successfully patent (2000) and commercially manufacture to GMP standards in 2010.
Cherry has been associated with AQIX® fluid technology since 1990 when she became involved with the development of multiple donor organ transporter unit by Res-Del Ltd, New Zealand. Her financial investments have continued and she has become a major shareholder in Aqix Ltd for the past 10 years. Cherry has always had great belief in the technology and gained a thorough understanding of how the technology will facilitate advancement in clinical practice for the good of mankind. She will bring some 25 years' experience of successfully running her own business in farming and land management and investing in small and large companies. Her loyalty to Aqix Ltd is exemplary and unwavering.
Jenny has over 30 years' experience in the cell culture industry in the UK and worldwide and was the past owner of Seralab Ltd., UK. She is the current owner of Life Science Group Ltd., UK, which is an independent manufacturing company based in the UK offering manufacturing of various human and animal sera and media for research, cell therapy and other disciplines. Jenny currently serves as President of the International Serum Industry Association (ISIA), a global association serving the interests of serum manufacturers, collectors and biotech industry and has responsibilities for European Regulatory Affairs, Traceability and Standardisation within the Association. The Board of Directors regard her appointment and proven experience in sales and marketing to be pivotal as the company moves forward in maximising the utilising of AQIX® technology.
Sarah Adamson qualified as a chartered accountant in 1992 and went on to work in the advertising industry for 16 years, firstly as an internal auditor for Interpublic Inc. and then as CFO of a media planning and buying company. After relocating to Kent, in 2010 she started her own accountancy practice and now works with businesses in a variety of sectors including forensic science, industry regulation and farming. Sarah also holds a Biochemistry Honours degree from King's College London and has a keen interest in biomedical science.
Dr. Masood has spent the last 13 years in drug discovery and then taking novel investigational medicinal products through pre-clinical and clinical development. As a medicinal chemist at Millennium Pharmaceuticals and latterly at Pfizer, he was a member of project teams that discovered MLN4924 (Phase 2 for Oncology) and PF- 389378 (Phase 1 for allergic Rhinitus). He also worked in the chemical technologies group at Pfizer where he evaluated new technologies and approaches in drug discovery. He then moved into drug development and worked in the Regulatory affairs department at Pfizer and more recently at GSK.
Professor Michael Mythen Medical is a Professor of Anaesthesia and Critical Care at UCL; Honorary Consultant Anaesthesia and Critical Care UCL Hospitals (UCLH) NHS Foundation Trust; Director, Centre for Anaesthesia UCL; Director of Research and Development UCLH NHS Foundation Trust; Director Joint UCLH/UCL Biomedical Research Unit; National Clinical Lead Enhanced Recovery Partnership Programme, UK Department of Health; Board Member of the Faculty of Intensive Care Medicine; Chair of the Intensive Care Foundation's Scientific Advisory Board; Chair of the Improving Surgical Outcomes Group; Editorial board member for The British Journal of Anaesthesia, Critical Care; Co-Chairman Evidence Based Peri-operative Medicine (EBPOM) annual meeting and website; Board Member, National Institute Academic Anaesthesia; Examiner for European Diploma of Intensive Care Medicine. Professor Michael (Monty) Mythen completed his UK anaesthesia fellowship (FRCA) in 1990, gained an MD in 1995 and was appointed assistant professor at Duke University Medical Centre, North Carolina, USA before returning to the UK. He has a wide range of research interests including: peri-operative fluid management and trans-oesophageal Doppler, haemostasis in the critically ill, endotoxin and endotoxin immunity and the determinants of post-operative morbidity and mortality. He has over 100 publications on PubMed and has extensive editorial involvement with a number of anaesthetic and critical care journals.